Soaring Sales of Obesity Drugs and Market News

This chapter discusses the impressive Q4 results of Eli Loonley, particularly their obesity drugs' sales growth. It also covers other market news including stock buyback plans, dividend raise, employee cuts, Treasury yield rise, financial moves by New York Community Bank Corp, and Oppenheimer's sector recommendations.